White & Case advises AGIC Capital on acquisition of majority stake in ATEC Pharmatechnik
1 min read
Global law firm White & Case LLP has advised AGIC Capital on the acquisition of a majority stake in German pharmaceutical company ATEC Pharmatechnik GmbH (ATEC).
Following the acquisition ATEC's CEO and founder Hans-Werner Mumm will remain as a minority shareholder and continue as CEO.
AGIC Capital is a growth-oriented private equity firm with US$2.2 billion of assets under management. ATEC is anticipated to be the first of several acquisitions AGIC Capital makes as it builds a specialty process technologies platform focused on pharmaceutical and biopharmaceutical end markets.
Germany-based ATEC is a leading manufacturer of aseptic processing solutions, primarily used in pharmaceutical manufacturing and bioprocessing applications, with a customer base that includes the top 10 global pharmaceutical companies.
The White & Case team which advised on the transaction was led by partners Stefan Koch and Jan Ole Eichstädt (both Frankfurt) and included partners Tilman Kuhn (Dusseldorf, Brussels), Andreas Lischka and Tim Bracksiek (both Frankfurt), local partners Thilo Wienke (Düsseldorf) and Marco Stephan (Frankfurt) and associates Christian Sperling, Michael Grambow, Viviane Cismak, Robin Jackson, Nane Juetting, Justus Redeker, Miriam Staatz, Justin Terada (all Frankfurt), Jana Rudt (Berlin), Lisa Baer (Dusseldorf), Marina Tatsumi, Guerkan Akbaba (both London) and Caitlin Powell Gimpel (Milan).
For more information please speak to your local media contact.